| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c9598f29748588cbd7ca6fa81d81e44 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate |
1999-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae1f7c24d628a244a18384ae2741cbcd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e25047d7520a2df8119b21cec803223
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5d4c4d1a0962f6cec919f1eb7fb5ccc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06ff78b0a31cac9622d3271e8374ea71 |
| publicationDate |
2000-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CZ-20001704-A3 |
| titleOfInvention |
A method of preventing or ameliorating conditions caused by enterohemorrhagic E. coli and a pharmaceutical composition for preventing and treating these conditions |
| abstract |
The solution deals with the treatment of diarrheal diseases andnassociated conditions caused by infection of pathogenic E. coli.nThe subject matter of the solution is the novel Means of Composition comprisingnboth the antibiotic and the toxin binding component, and methodsntreatment using simultaneous administration of the toxin binding componentnwhenever an antibiotic is administered to the patient. Mentionednthe means kill the intestinal bacteria E. coli they causensaid states and neutralize the SLT produced by thesenorganisms and / or released from such organisms, if anynkilled. They further improve the symptoms of infection and inhibit developmentnsaid infection in hemolytic uremic syndrome (HUS). |
| priorityDate |
1999-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |